Mesoblast Limited
Pembelian
Diupdate

MSB gets Fast Track from FDA

240
Looks like price is respecting trendline / uptrend.

Price is within range. Needs to break above resistance and stay above for bullish confirmation.

Next target I would imagine a sell off unless FDA approval or some super bullish news is released and it gaps up (possible with these lower cap stocks).

Overall lots of bullish news, Novartis partnership + FDA Fast Track for Remestemcell-L
Catatan
Sadly bad news came out and the trend was invalidated - trading just above 78.6% area. I'm in quite a rough drawdown on my positions but you live and you learn. Biotcech stocks are highly risky!

Pernyataan Penyangkalan

Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.